Evidence map›Paper›PMID 42138191›Full record

ReviewFuture oncology (London, England)2026

Shared decision-making in prostate cancer treatment: selecting an androgen deprivation therapy option.

Sean P Collins, Martine C Maculaitis, Marty Chakoian

Abstract readReview
In one paragraph

Review in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sean P CollinsDepartment of Radiation Oncology, University of South Florida, Tampa, FL, USA.ORCID 0000-0001-7103-939X
Martine C MaculaitisOracle Life Sciences, Austin, TX, USA.ORCID 0000-0001-8388-5315
Marty ChakoianUs TOO in Seattle ZERO Prostate Cancer Support Group, Seattle, WA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This podcast will provide an overview of androgen deprivation therapy (ADT) for advanced prostate cancer, including the different treatment options currently available. The podcast will also cover the key results of recently published studies that looked at patient preferences for different characteristics of ADT. Additionally, a physician and patient will each discuss the importance of shared decision-making in selecting the optimal ADT option. They will address key factors to discuss when evaluating ADT options, and emphasize the importance of aligning treatment choices with patients' individual needs and the best available scientific evidence.

Indexed as

Androgen AntagonistsDecision Making, SharedProstatic NeoplasmsAntineoplastic Agents, HormonalGonadotropin-Releasing HormoneHumansMalePatient PreferenceAndrogen AntagonistsAntineoplastic Agents, HormonalGonadotropin-Releasing HormoneAdvanced prostate cancerandrogen deprivation therapyGnRH agonistsGnRH antagonistspatient preferencespodcastshared decision-making

Identifiers

PMID42138191
PMCPMC13211318

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.